Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated...

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) represents a major clinical challenge due to its limited response to conventional treatment and poor prognosis. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment modality in patients with somatostatin receptor (SSTR)-positive tumors. We present an 82-year-old female patient with RAIR-DTC who underwent six cycles of PRRT after demonstrating SSTR positivity on Ga-68 DOTATATE positron emission tomography/computed tomography. This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.